Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

Yi-Hsing Chen,1 Hellen MDS de Carvalho,2 Umut Kalyoncu,3 Lyndon John Q Llamado,4 Gaston Solano,5 Ron Pedersen,6 Galina Lukina,7 Juan J Lichauco,8 Radu S Vasilescu9 1Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung City, Taiwan; 2Unidade de Reumatologia,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chen YH, Carvalho HMS, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Tuberculosis
hepatitis C
hepatitis B
tumor necrosis factor inhibitors
reactivation
risk
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/47bee8f6070247f79365ffbdb445e498
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:47bee8f6070247f79365ffbdb445e498
record_format dspace
spelling oai:doaj.org-article:47bee8f6070247f79365ffbdb445e4982021-12-02T02:46:43ZTuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice1177-5491https://doaj.org/article/47bee8f6070247f79365ffbdb445e4982018-01-01T00:00:00Zhttps://www.dovepress.com/tuberculosis-and-viral-hepatitis-infection-in-eastern-europe-asia-and--peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Yi-Hsing Chen,1 Hellen MDS de Carvalho,2 Umut Kalyoncu,3 Lyndon John Q Llamado,4 Gaston Solano,5 Ron Pedersen,6 Galina Lukina,7 Juan J Lichauco,8 Radu S Vasilescu9 1Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung City, Taiwan; 2Unidade de Reumatologia, Hospital de Base do Distrito Federal, Brasilia, Brazil; 3Department of Internal Medicine, Faculty of Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey; 4Pfizer, Makati City, Philippines; 5Pfizer, San Jose, Costa Rica; 6Pfizer, Collegeville, PA, USA; 7Moscow Clinical Scientific Center, Moscow, Russia; 8Section of Rheumatology, Department of Medicine, St. Luke’s Medical Center, Quezon City, Manila, Philippines; 9Pfizer, Brussels, Belgium Abstract: Tumor necrosis factor-α (TNF-α) inhibitors are increasingly becoming the standard of care for treating a number of inflammatory diseases. However, treatment with TNF-α inhibitors carries an inherent risk of compromising the immune system, resulting in an increased susceptibility to infections and malignancies. This increased risk of infection is of particular concern in Asia, Eastern Europe, and Latin America where tuberculosis (TB) and viral hepatitis are endemic. In this brief review, we examine the literature and review the impact of TNF-α inhibitors on the incidence and the reactivation of latent disease with respect to TB, hepatitis C infection, and hepatitis B infection. Our findings show that TNF-α inhibitors are generally safe, if used with caution. Patients should be screened prior to the initiation of TNF-α inhibitor treatment and given prophylactic treatment if needed. In addition, patients should be monitored during treatment with TNF-α inhibitors and after treatment has stopped to ensure that infections, if detected, are treated promptly and effectively. Our analysis is consistent with other reports and guidelines. Keywords: tuberculosis, hepatitis C, hepatitis B, tumor necrosis factor inhibitors, reactivation, riskChen YHCarvalho HMSKalyoncu ULlamado LJQSolano GPedersen RLukina GLichauco JJVasilescu RSDove Medical PressarticleTuberculosishepatitis Chepatitis Btumor necrosis factor inhibitorsreactivationriskMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 12, Pp 1-9 (2018)
institution DOAJ
collection DOAJ
language EN
topic Tuberculosis
hepatitis C
hepatitis B
tumor necrosis factor inhibitors
reactivation
risk
Medicine (General)
R5-920
spellingShingle Tuberculosis
hepatitis C
hepatitis B
tumor necrosis factor inhibitors
reactivation
risk
Medicine (General)
R5-920
Chen YH
Carvalho HMS
Kalyoncu U
Llamado LJQ
Solano G
Pedersen R
Lukina G
Lichauco JJ
Vasilescu RS
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
description Yi-Hsing Chen,1 Hellen MDS de Carvalho,2 Umut Kalyoncu,3 Lyndon John Q Llamado,4 Gaston Solano,5 Ron Pedersen,6 Galina Lukina,7 Juan J Lichauco,8 Radu S Vasilescu9 1Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung City, Taiwan; 2Unidade de Reumatologia, Hospital de Base do Distrito Federal, Brasilia, Brazil; 3Department of Internal Medicine, Faculty of Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey; 4Pfizer, Makati City, Philippines; 5Pfizer, San Jose, Costa Rica; 6Pfizer, Collegeville, PA, USA; 7Moscow Clinical Scientific Center, Moscow, Russia; 8Section of Rheumatology, Department of Medicine, St. Luke’s Medical Center, Quezon City, Manila, Philippines; 9Pfizer, Brussels, Belgium Abstract: Tumor necrosis factor-α (TNF-α) inhibitors are increasingly becoming the standard of care for treating a number of inflammatory diseases. However, treatment with TNF-α inhibitors carries an inherent risk of compromising the immune system, resulting in an increased susceptibility to infections and malignancies. This increased risk of infection is of particular concern in Asia, Eastern Europe, and Latin America where tuberculosis (TB) and viral hepatitis are endemic. In this brief review, we examine the literature and review the impact of TNF-α inhibitors on the incidence and the reactivation of latent disease with respect to TB, hepatitis C infection, and hepatitis B infection. Our findings show that TNF-α inhibitors are generally safe, if used with caution. Patients should be screened prior to the initiation of TNF-α inhibitor treatment and given prophylactic treatment if needed. In addition, patients should be monitored during treatment with TNF-α inhibitors and after treatment has stopped to ensure that infections, if detected, are treated promptly and effectively. Our analysis is consistent with other reports and guidelines. Keywords: tuberculosis, hepatitis C, hepatitis B, tumor necrosis factor inhibitors, reactivation, risk
format article
author Chen YH
Carvalho HMS
Kalyoncu U
Llamado LJQ
Solano G
Pedersen R
Lukina G
Lichauco JJ
Vasilescu RS
author_facet Chen YH
Carvalho HMS
Kalyoncu U
Llamado LJQ
Solano G
Pedersen R
Lukina G
Lichauco JJ
Vasilescu RS
author_sort Chen YH
title Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
title_short Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
title_full Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
title_fullStr Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
title_full_unstemmed Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
title_sort tuberculosis and viral hepatitis infection in eastern europe, asia, and latin america: impact of tumor necrosis factor-α inhibitors in clinical practice
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/47bee8f6070247f79365ffbdb445e498
work_keys_str_mv AT chenyh tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT carvalhohms tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT kalyoncuu tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT llamadoljq tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT solanog tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT pedersenr tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT lukinag tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT lichaucojj tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
AT vasilescurs tuberculosisandviralhepatitisinfectionineasterneuropeasiaandlatinamericaimpactoftumornecrosisfactoralphainhibitorsinclinicalpractice
_version_ 1718402157955252224

Ejemplares similares